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Abstract: Objective: To investigate the effect of Lewis y overexpression on the expression of 
proliferation-related factors in ovarian cancer cells. Methods: mRNA levels of cyclins, CDKs, 
and CKIs were measured in cells before and after transfection with the α1,2-fucosyltransferase 
gene by real-time PCR, and protein levels of cyclins, CDKs and CKIs were determined in 
cells before and after gene transfection by Western blot. Results: Lewis y overexpression led 
to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin 
E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and 
p21, and decrease of p27 at only the protein expression level without change in its mRNA 
level. There were no differences in proteins and the mRNA levels of CDK2, CDK4 and 
CDK6 before and after gene transfection. Anti-Lewis y antibody, ERK and PI3K pathway 
inhibitors PD98059 and LY294002 reduced the difference in cyclin and CKI expression 
caused by Lewis y overexpression. Conclusion: Lewis y regulates the expression of  
cell cycle-related factors through ERK/MAPK and PI3K/Akt signaling pathways to promote 
cell proliferation. 
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1. Introduction 
Lewis y is a difucosylated oligosaccharide present on the surface of cells, and its expression is 
increased in many tumors. Lewis y can regulate gene and/or protein expression through glycosylation 
modification of cell surface receptors, consequently affecting downstream intracellular signaling pathways. 
α1,2-fucosyltransferase (α1,2-FT) is a key enzyme in the synthesis of Lewis y. In our previous study, 
human α1,2-FT was transfected into the ovarian cancer cell line RMG-I by gene transfection technology, 
and the ovarian cancer cell line RMG-IH with stable and high expression of Lewis y was established. 
Thus, it was found that Lewis y overexpression accelerates cell entry into S phase from the G0-G1 phase, 
shortens the cell cycle and enhances cell proliferation [1]. 
The control of the cell cycle is closely related to tumor cell proliferation, differentiation and apoptosis. 
Abnormal cell cycle regulation is an important mechanism of tumorigenesis. Cell cycle progression is 
coordinately controlled by many protein factors, which mainly include cyclins, cyclin-dependent 
kinases (CDKs), cyclin-dependent kinase inhibitors (CKIs), etc. The key to cell cycle regulation is CDK 
activation during specific cell cycle changes, and the phasic activation of CDKs depends on cyclins. The 
activities of CDKs can also be inhibited by CKIs. CKIs can exert their functions by binding to CDK 
alone, or by binding to cyclin-CDK complexes. Two kinds of CKI families have been found so far: one 
is the INK4 (an inhibitor of CDK4) protein family, including p15, p16, p18 and p19, where each of them 
contains four ankyrin repeats in its protein structure, mainly specifically inhibiting the phosphorylation 
kinase activity of the cyclin D1-CDK4/6 complex; the other one is the CIP/KIP protein family, mainly 
including p21, p27 and p57, which have a nuclear localization signal (NLS) at the C-terminus, and a 
conserved region proximal to the amino-terminus. This group of proteins can exert their inhibitory 
activities by their interactions with a variety of cyclin-CDK complexes, and thereby induce S phase 
arrest [2–4]. 
In our previous study, we had found that Lewis y is a carbohydrate structure of some cell surface 
receptors, such as EGFR [5], IGF-1R [6], integrin α5 and β1, etc. [7], and its overexpression can further 
activate signaling molecules including Akt and ERK, and then activate the downstream ERK/MAPK 
and PI3K/Akt signaling pathways [8]. It has been reported that the activation of ERK1/2 affects  
cell proliferation, apoptosis and migration [9–11]. PI3K/Akt is also considered to be critical in cell 
proliferation and differentiation [12–14]. The anticancer drug pemetrexed reduces Cdk2 and cyclin-A 
expression by inhibiting ERK activity, and inhibits the activity of the complex [15]. Chen et al. [16] 
confirmed in vivo and in vitro that formononetin, an important component of anti-cancer drugs, inhibits 
the expression of cyclin D1 through the IGF1/PI3K/Akt pathway. 
Therefore, we speculated that the acceleration of cell growth induced by Lewis y overexpression may 
be related to changes in the expression of cell cycle-related factors resulting from activation of the 
ERK/MAPK and PI3K/Akt signaling pathways. On the basis of preliminary work, this study further 
investigated the relevant molecular mechanisms of accelerated cell proliferation after overexpression of Int. J. Mol. Sci. 2012, 13 830 
 
Lewis y in RMG-I cells, including the effects of its expression on cyclins, cyclin-dependent kinases, 
protein and mRNA expression status of their inhibitors and corresponding signaling pathways. This 
study revealed the molecular basis of cell cycle regulation, including that Lewis y overexpression 
accelerated the proliferation rate of ovarian cancer cells, reduced the proportion of G0/G1-phase cells 
and increased the proportion of S-phase cells. 
2. Results 
2.1. Lewis Y Overexpression Promoted Ovarian Cancer Cells to Enter S Phase 
The percentage of RMG-IH cells in G1-phase after gene transfection were significantly reduced 
compared to either untransfected RMG-I or empty vector-transfected RMG-IM (all p < 0.05), while  
the corresponding percentages of cells in S and G2 phases were significantly increased. These results 
suggested that Lewis y overexpression, induced by α1,2-fucosyl-transferase gene transfection, promoted 
RMG-I cell proliferation by altering cell cycle regulation and increasing cell division (Figure 1). 
Figure 1. Lewis y overexpression increases the proliferation of RMG-I cells. Cell cycle 
analysis. RMG-I-M: RMG-I cells transfected with pcDNA3.1 vector; RMG-I-H: RMG-I 
cells with high expression of the transfected pcDNA3.1/FUT1. Cells were prepared, stained 
with PI and analyzed by a FAC Scan flow cytometer.  
 
2.2. Lewis Y Overexpression Increased mRNA Expression Levels of Cyclins, p16 and p21 Without 
Affecting Both CDKs and p27 mRNA Expression in Ovarian Cancer Cells 
Cyclins, CDKs and CKIs all play important roles in the cell cycle, so cell cycle factors closely related 
to G1/S phases were detected by the real-time PCR method. It was found that mRNA expression levels Int. J. Mol. Sci. 2012, 13 831 
 
of cyclin A, cyclin D1 and cyclin E increased in Lewis y overexpressed cells, which were 2.46, 2.71, and 
2.75 times those in cells before transfection (all p < 0.05), while mRNA expression levels of p16 and p21 
in transfected cells were respectively 33.5% and 25.2% of those of cells before transfection with both 
significantly decreased (both p < 0.05). In addition, p27 mRNA levels after transfection tended to 
decrease, being 87.8% of that before transfection (p > 0.05); CDK2, CDK4 and CDK6 expression did 
not change obviously, which compared to pre-transfection was 92.7%, 1.11 times and 1.26 times, 
respectively (p > 0.05). The results indicated that Lewis y overexpression affected the expression of 
cyclins and p16 and p21 at the gene level (Figure 2). 
Figure 2. The mRNA expression of Cyclins, cyclin-dependent kinases (CDKs) and 
cyclin-dependent kinase inhibitors (CKIs) in RMG-I, RMG-I-M, RMG-I-H cells were tested 
by quantitative Real- Time PCR. RMG-I, RMG-I-M, RMG-I-H: same as Figure 1. Three 
independent experiments were performed and the results were reproducible. (* p < 0.05;  
† p > 0.05). 
 
2.3. Lewis Y Overexpression Promoted Cyclin and CKI Expression Without Affecting CDK Expression 
in Ovarian Cancer Cells 
The protein expression levels of cyclins (cyclins A, D1 and E), CDKs (CDK2, CDK4 and CDK6) and 
CKIs (p16, p21 and p27) were determined by Western blotting. The results showed that the protein 
expression levels of cyclin A, cyclin D1, and cyclin E were consistent with their mRNA levels in the 
transfected RMG-IH cells, which were 2.6, 3.1 and 2.5 times those in the untransfected cells (all p < 0.05). 
Meanwhile, the protein expression levels of p16, p21 and p27 were similar to their mRNA levels, which 
were significantly reduced to 44%, 23% and 31% of those prior to transfection (all p < 0.05), and the 
protein expression levels of CDK2, CDK4, and CDK6 were 1.09 times, 98% and 97% compared to those 
in the untransfected cells, consistent with their gene expression levels, i.e., without significant change 
after transfection (p > 0.05) (Figure 3). Int. J. Mol. Sci. 2012, 13 832 
 
Figure 3. The expression of Cyclins (A), CDKs (B) and CKIs (C) in RMG-I, RMG-I-M, 
RMG-I-H cells were tested by Western blot; (D) Quantification of A, B and C. RMG-I, 
RMG-I-M, RMG-I-H: same as Figure 1. Three independent experiments were performed 
and the results were reproducible. (* p < 0.05; 
† p > 0.05). 
 
2.4. Lewis Y Antibody Blocking Reduced Lewis Y Overexpression-Mediated Differences in Cyclin and 
CKI Protein Expression  
Lewis y antibody was used to conduct a blocking study in Lewis y-overexpressed cells. The antibody 
block the activation of Lewis y and interfering with the dynamics and signaling of EGFR or some other 
cell surface receptor which carbohydrate structure contained Lewis y. The results showed that the 
protein expression levels of cyclin A, cyclin D1 and cyclin E were reduced in the treated cells compared 
to those in the cells without blocking treatment (all p < 0.05), whereas p16, p21 and p27 protein  
levels increased (all p < 0.05), and the expression differences relative to the untransfected cells were 
significantly reduced (Figure 3). 
2.5. The Differences in Cyclin and CKI Protein Expression Levels Were Decreased by Treatment with 
LY294002 and PD98059 in Lewis Y Overexpressed Ovarian Cancer Cells 
The ERK/MAPK pathway inhibitor PD98059, PI3K/Akt pathway inhibitor LY294002 and DMSO 
were used to treat Lewis y-overexpressed cells, respectively. The results showed that the differences  
in the proteins expression levels of cyclin A, cyclin D1, cyclin E, p16, p21 and p27 before and after 
treatment were also apparently reduced in the cells (Figure 4). Int. J. Mol. Sci. 2012, 13 833 
 
Figure 4. Effect of the ERK, PI3K/Akt signaling pathways and Lewis y antibody on Lewis y 
induced expression of Cyclins and CKIs protein expression. (A) Western blot profiles  
of Cyclins and CKIs. RMG-I, RMG-I-H: same as Figure 1.RMG-I-H cells were pretreated  
with PD98059 (25 μM), LY294002 (50 μM), or anti-Lewis y antibody (10 μg/mL) for 24 h; 
(B) Quantification of A. Data were expressed as the mean ± SD from three   
independent experiments. 
 
3. Discussion 
The progression of the cell cycle is regulated by many factors. There are two main regulation points: 
one at the G1/S restriction point, which controls cells from entering the S phase, and the other at the G2/M 
turning point. Non-proliferative cells are in the G0 phase, and when stimulated by growth factors, etc., 
they can enter the S phase through the G1/S restriction point, exiting the G1 phase. In mammalian cell 
cycle regulation, the regulation points between G1-S phase are key points for the control of cell 
proliferation. Abnormalities in these regulation points are closely related to the formation and 
development of tumors. Our previous work had found that Lewis y overexpression significantly reduces 
ovarian cancer cell number in G0-G1 phase, and significantly increases the percentage of cells in S and 
G2 phases compared to that in untransfected cells [1], indicating that the cell cycle is in a proliferative 
state. In this study, we found that the mRNA and protein expression levels of cyclin A, cyclin D1 and 
cyclin E significantly increased in Lewis y-overexpressed cells and that the mRNA and protein 
expression levels of CDK2, CDK4 and CDK6 did not change. Cyclin A, E and D1 are positive 
regulatory proteins that promote G1/S transition in the cell cycle, and CDKs are the core of the cell cycle 
regulatory network. Different cyclin proteins bind to their corresponding CDKs and form corresponding 
cyclin-CDK complexes to activate the activities of CDK kinases, and they are thus involved in cell cycle 
regulation. By binding to CDK2 to form a complex, cyclin A initiates S-phase DNA replication to 
complete the S phase, and assists in G2/M phase transition [17]. In our in vitro culture system, the cyclin 
A mRNA and protein expression levels in Lewis y-overexpressed cells significantly increased compared 
to those in the untransfected cells, which was consistent with the increased proportion of cells in the 
G2/M phase. Cyclin D1 binds to corresponding CDK4 or CDK6 to form a complex, activates Rb Int. J. Mol. Sci. 2012, 13 834 
 
proteins, initiates the transcription of S phase-related genes, and then allows the cells to enter into an 
autonomous division and proliferation program, resulting in CDK kinase activation and the cell division 
entering S phase from G1 phase [18]. Currently, cyclin D1 protein overexpression has been found in the 
majority of tumors (breast, gastric, esophageal and ovarian cancer, and B-cell lymphoma). Cyclin E 
mainly forms a complex with CDK2 to drive the G1-S phase, initiate DNA synthesis in S phase, and 
promote cell cycle progression [19]. Gene amplification and protein expression disorder of cyclin E can be 
found in breast, colon, gastric and ovarian cancer, among others [20]. This study found that the increased 
mRNA and protein expression levels of cyclin D1 and cyclin E caused by Lewis y overexpression were 
consistent with the decreased proportion of G1 phase in ovarian cancer cells resulting from Lewis y 
overexpression. After the cells were treated with anti-Lewis y monoclonal antibody, the mRNA and 
protein expression levels of cyclin A, cyclin D1 and cyclin E were significantly reduced, which further 
confirmed our conclusions. 
Negative regulatory factors also play important roles in cell cycle control. At present, many studies 
have shown that p16, p21 and p27 most likely directly act on the regulation of the G1/S phase restriction 
point [21–23]. P16 can bind to CDK4/6, and the cyclin D1-CDK complex, thereby inhibiting the 
phosphorylation of Rb proteins and the release of transcription factor E2F, which in turn induces G1-S 
phase arrest. The P21 protein is an inhibitor that binds to almost every cyclin-CDK complex, and makes 
the complex lose its kinase activity, which leads to cell cycle arrest in G2 phase. P27 arrests the cell 
cycle in G1 phase and inhibits cell proliferation by binding to the activated cyclin-CDK2 complex and 
cyclin-CDK4 complexes and then inhibiting their activities. In this study, it was found that in Lewis 
y-overexpressed cells, both mRNA and protein expression levels of P16 and P21 were reduced; although 
reduction in P27 mRNA was not obvious, its protein level was significantly decreased. After the  
cells were treated with anti-Lewis y monoclonal antibody, the above changes were reversed, which  
further confirmed that the promotion of G1-S transition by Lewis y was related to the inhibition of p16, 
p21 and p27. 
The synthesis, assembly, modification and activation, disassembly, degradation and conversion of 
cyclins, CDKs, and CKIs are the core mechanisms that lead to the progression of cell cycle phases and 
the phase transitions and are regulated by signal transduction from extracellular growth factors. These 
signaling molecules, including mitogens and anti-mitogens, transduce the corresponding signals 
downward after binding to their receptors, and ultimately affect the cell cycle through a complex 
network system. The PI3K/Akt and ERK/MAPK signal transduction pathways are important pathways 
for cell survival and apoptosis inhibition. Studies have shown that IGF-1 upregulates cyclin D1 and 
cyclin E expression via the MAPK signaling pathway [24]; p21 is a direct substrate for Akt proteins, and 
activated Akt phosphorylates the Thr145 site in p21 proteins, which promotes the extranuclear transport 
of p21, leads to the accumulation of the proteins in cytoplasm, and thus facilitates p21 degradation [25]. 
TGF-β is an anti-mitogen that can arrest cells in late G1 phase, which is caused by p27 binding to the 
CDK2-cyclin E complex and inhibiting the activity of the latter [26,27]. The ERK/MAPK and PI3K/Akt 
signaling pathway inhibitors were used in the transfected cells for corresponding inhibition, and it was 
found that the differences in cyclin and CKI expression levels were significantly reduced. Combined 
with our previous findings that Lewis y overexpression leads to a significant increase in phosphorylation 
levels of Akt and ERK1/2 [5], increase in Lewis y antigen, as a part of the structure of IGF-1R, EGFR and Int. J. Mol. Sci. 2012, 13 835 
 
other cell surface receptors [6,8], not only activates the receptor tyrosine kinase activities but also further 
activates its downstream PI3K/Akt and Raf/MEK/MAPK signaling pathways. We speculate that increased 
expression of Lewis y antigen accelerates gene transcription in nuclei by activating the above pathways, 
stimulates DNA synthesis, alters expression levels and activities of cycle-related proteins, and ultimately 
promotes cells to skip the G1 phase restriction point and enter into S phase for cell proliferation. 
The results of this study provide a detailed theoretical basis of how Lewis y overexpression causes 
accelerated proliferation of ovarian cancer cells. Lewis y regulates the expression of cell cycle-related 
factors through the ERK/MAPK and PI3K/Akt signaling pathways, thereby affecting cell proliferation. 
4. Materials and Method  
4.1. Reagents and Cell Lines 
The RMG-I cell line, which was originated from human ovarian clear cell carcinoma, donated by 
Professor Iwamori Masao of Tokyo University of Japan. α1,2-FT gene transfected RMG-I cell line was 
established as previously reported [25], named as RMG-I-H. RMG-I-M was the cell line transfected 
with the vector alone. The following reagents were purchased from commercial sources: DMEM and 
fetal bovine serum (FBS) from Hyclone (Logan, UT, USA); trypsin and ethylenediamine tetraacetic acid 
(EDTA) from Amresco; Mouse anti-human Lewis(y) mAb (clone A70-C/C8) was purchased from 
Abcam (England). The anti-p16, p21, p27 and β-actin were purchased from Santa Cruz (USA). The 
anti-Cyclin A and Cyclin D1 were purchased from Bioworld (USA). The anti-Cyclin E and CDK2 were 
purchased from Epitomics (USA). The anti-CDK4 and CDK6 were purchased from Thermo (USA). 
Ly294002 and PD98059 were obtained from Sigma (USA). Trizol reagent, PrimeScript™
 RT reagent 
kit, and SYBR
® Premis Ex Taq™ from TaKaRa Biotechnology Co. (China). The sequences of primers 
were synthesized by Invitrogen Co. (China). 
4.2. Cell Culture 
Cells were cultured in DMEM supplemented with 10% FBS at 37 °C, 5% CO2 in humidified air. 
Cells are grouped in western blot as follows: Lewis y antibody-treated groups (cells were treated with 
10 μg/mL Lewis y monoclonal antibody at 37 °C in 5% CO2 for 24 h), irrelevant isotype-matched 
control (10 μg/mL normal mouse IgM), PD98059-treated goups (25 μM at 37 °C in 5% CO2 for 24 h), 
LY294002-treated goups (50 μM at 37 °C in 5% CO2 for 24 h). 
4.3. Analysis the Effect of Lewis Y Antigen on Cell Proliferation 
A total of 1 × 10
5 cells in 1 mL were inoculated into a 6-well plate in serum-free medium, with each 
group in triplicate, and cultivated for 24 h. The cells were synchronized in G1 phase and then further 
cultivated in medium with 10% serum for 24 h. The three groups of cells were collected, washed twice 
with PBS, detached with trypsin to prepare a single cell suspension, and centrifuged at 1000 rpm for 
5 min. The supernatant was discarded. After being fixed in 70% cold ethanol and stained with PI 
(propidium iodide) solution, the cells in suspension were submitted to flow cytometry for quantitative 
cell cycle analysis. Int. J. Mol. Sci. 2012, 13 836 
 
4.4. Determination and Real-Time PCR 
Total RNA was extracted from the transfected and control cells using Trizol reagent. cDNA was 
synthesized according to the RNA reverse transcription kit instructions and was used as a template for 
PCR analysis. Then the cDNA was subjected to Real-time PCR analysis using the SYBR Green PCR 
Master Mix on the ABI Prism 7500 Sequences Detection System. The PCR primer sequences were 
designed according to the human Cyclin A, D1, E, CDK2, CDK4, CDK6, p16, p21 and p27 gene 
sequences reported in GenBank and chemically synthesized (Table 1). The specificity of the PCR  
was confirmed by examining the dissociation reaction plot subsequent to Real-time PCR. Human 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) served as the constitutive control. PCR 
reactions of each sample were done in triplicate. Data were analyzed through the comparative threshold 
cycle (CT) method.  
Table 1. Characteristic of primers used for Real-time PCR amplification. 
Gene name  Sequence of primers(5'-3') 
Product 
length (bp) 
Annealing 
temperature (°C)
Cyclin A 
F: AGGTACTGAAGTCCGGGAAC 
R: GTGACATGCTCATCATTTACAGGAA 
106 62 
Cyclin D1 
F: TGATGCTGGGCACTTCATCTG 
R: TCCAATCATCCCGAATGAGAGTC 
177 63 
Cyclin E 
F: TTTGCAGGATCCAGATCAAGA 
R: CACAGACTGCATTATTGTCCCAAG 
92 60 
CDK2 
F: CTCCACCGAGACCTTAAACCTCAG 
R: TCGGTACCACAGGGTCACCA 
138  60 
CDK4 
F: CTTCTGCAGTCCACATATGCAACA 
R: CAACTGGTCGGCTTCAGAGTTTC 
114  60 
CDK6 
F: GATCTCTGGAGTGTTGGCTGCATA 
R: GGCAACATCTCTAGGCCAGTCTTC 
144  62 
P16 
F: GGCACCAGAGGCAGTAACCA 
R: GGACCTTCGGTGACTGATGATCTAA 
126  63 
P21 
F: AAGACCATGTGGACCTGTCACTGT 
R: GAAGATCAGCCGGCGTTTG 
155  62 
P27 
F: CAAATGCCGGTTCTGTGGAG 
R: TCCATTCCATGAAGTCAGCGATA 
177 63 
4.5. Analysis of the Proteins of Cell Cycle Relation Factors with Western Blotting  
Cells were washed twice with ice-cold PBS, scraped in lysis buffer (50 mM Tris-HCl (pH 7.4),  
150 mM NaCl, 0.5% NP40, 100 mM NaF, 200 μM Na3VO4, and 10 μg/mL each aprotinin, leupeptin, 
PMSF, and pepstatin), and incubated for 30 min at 4 °C while rocking. Lysates were cleared by 
centrifugation (10 min at 12,000 rpm, 4 °C). For immunoblot analysis, 50 μg of total protein were 
resolved by SDS-PAGE and transferred to poly (vinylidene difluoride) membranes. Membranes were 
blocked with TTBS (25 mM Tris-HCl, 150 mM NaCl (pH 7.5), and 0.1% Tween 20) containing 5% 
nonfat milk and incubated overnight at 4 °C with antibody Cyclin A (1:500), Cyclin D1 (1:500), Cyclin 
E (1:1000), CDK2 (1:1000), CDK4 (1:200), CDK6 (1:200), p16 (1:200), p21 (1:200) and p27 (1:200) Int. J. Mol. Sci. 2012, 13 837 
 
in TBST/1% nonfat milk. Blots were washed in TTBS and incubated with the appropriate horseradish 
peroxidaselinked IgG, and immunoreactive proteins were visualized with ECL detection system. The 
protein bands were quantified with densitometric analysis. The expression of each protein was 
calculated by the ratio of the intensity of this protein to that β-actin. 
4.6. Statistical Analysis  
All experiments were performed in triplicate and all data are expressed as mean ± standard errors. 
Raw data were analyzed by the unpaired Student’s t test using SPSS 11.0 software (USA). A  
p-value < 0.05 was considered to be statistically significant. 
5. Conclusions  
Lewis y overexpression increased cell proliferation by regulation cell cycle regulated factors with the 
cooperation of ERK/MAPK and PI3K/Akt pathways.  
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